911010-88-3

Basic information

• Product Name: 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester
• Synonyms: 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester;Ethyl 5-aMino-1-benzyl-1,2,3,6-tetrahydropyridine-4-carboxylate
• CAS NO: 911010-88-3
• Molecular Formula: C₁₅H₂₀N₂O₂
• Molecular Weight: 260.3315
• Mol File: 911010-88-3.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester(911010-88-3)
• EPA Substance Registry System: 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester(911010-88-3)

Safety Data

• Hazardous Substances Data: 911010-88-3(Hazardous Substances Data)

Usage

General Description

5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester, also known as Etolipis, is a chemical compound with the molecular formula C16H20N2O2. It is an ethyl ester derivative of Tetrahydropyridine-4-carboxylic acid and contains an amino group and a benzyl group attached to the tetrahydropyridine ring. 5-Amino-1-benzyl-1,2,3,6-tetrahydro-pyridine-4-carboxylic acid ethyl ester has potential pharmacological properties and is being studied for its potential use in the treatment of various conditions, including neurological disorders and cancer. Its precise mechanisms of action and therapeutic applications are still under investigation, and further research is ongoing to fully understand the properties and potential uses of this chemical compound.

Upstream product

• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 
• 39514-19-7 ethyl 1-benzyl-3-oxo-4-piperidinecarboxylate 

Downstream Products

• 911010-89-4 methyl 7-benzyl-4-hydroxy-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carboxylate 

Relevant articles and documents

Heterocyclic compound, pharmaceutical composition and application

The invention discloses a heterocyclic compound which is a heterocyclic compound shown as a formula I, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a hydrate, a solvate, a metabolite or a prodrug thereof. The heterocyclic compound can be used for preparing medicines for treating and/or preventing cancers related to KRAS G12C mutation. The invention also discloses a pharmaceutical composition containing the heterocyclic compound, and application of the compound shown in the formula I, or pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, metabolite, prodrug or pharmaceutical composition thereof in preparation of drugs.

Fused cyanopyridine compound and preparation method and application thereof

The invention discloses a fused cyanopyridine compound shown as a general formula I-1 or I-2, or a pharmaceutically acceptable salt thereof, or an enantiomer, a diastereoisomer, a tautomer, a torsional isomer, a solvate, a polymorphic substance or a prodrug thereof, and a preparation method and a pharmaceutical application of the fused cyanopyridine compound, wherein the definition of each group is shown in the specification.

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have s